Literature DB >> 8996002

The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.

A A Renshaw1, B R Dean, K H Antman, D J Sugarbaker, E S Cibas.   

Abstract

STUDY
OBJECTIVE: Treatment of malignant mesothelioma (MM) at an early stage results in increased survival. Cytologic examination of pleural effusions is one of the first diagnostic techniques attempted in these patients. The objective of this study was to define the role of cytologic examination of pleural fluid in facilitating early diagnosis.
DESIGN: The medical records and cytologic slides of patients with pleural MM were reviewed.
SETTING: Medical records were reviewed from two institutions: a large general hospital and a cancer hospital. PATIENTS: Twenty-nine patients ranging in age from 32 to 81 years (mean, 59 years) met the study criteria.
INTERVENTIONS: All patients had at least one cytologic pleural fluid examination. MEASUREMENTS AND
RESULTS: The median time from initial symptoms to the diagnosis of MM was 8 weeks for all patients. For patients with a positive or suspicious cytologic result, the median was 4 weeks, and in those with a negative cytologic result, it was 12 weeks. The overall sensitivity of cytologic examination for the diagnosis of MM was 32%. Cytogenetic analysis of pleural fluid had a sensitivity of 56%, and was positive in 1 case in which results of cytologic examination were negative. Patients in whom the time from presentation to diagnosis was greater than 1 year all had negative cytologic results followed by long periods without further workup, despite a history of exposure to asbestos.
CONCLUSIONS: A positive or suspicious cytologic result was associated with a decreased median time to diagnosis. Unfortunately, the sensitivity of cytologic examination for a diagnosis of MM was only 32%. Until better diagnostic techniques are developed, we recommend immediate pleural biopsy in patients in whom MM is suspected and cytologic evaluation of pleural fluid gives negative results.

Entities:  

Mesh:

Year:  1997        PMID: 8996002     DOI: 10.1378/chest.111.1.106

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  41 in total

Review 1.  Statement on malignant mesothelioma in the United Kingdom.

Authors: 
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.

Authors:  Emin Tamer Elkiran; Mehmet Ali Kaplan; Alper Sevinc; Sercan Aksoy; Umut Demirci; Mesut Seker; Hakan Harputluoglu; Nuriye Yildirim Ozdemir; Feridun Isik; Arife Ulas; Mevlude Inanc; Ulku Yalcintas Arslan; Gamze Gokoz Dogu; Abdurrahman Isikdogan; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2012-06-22       Impact factor: 3.064

Review 3.  Thoracoscopy: medical versus surgical-in the management of pleural diseases.

Authors:  Samira Shojaee; Hans J Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 4.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

5.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 6.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 7.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 8.  Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Authors:  Paul Halford; Amelia O Clive
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 9.  Pleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions?

Authors:  Giles Dixon; Duneesha de Fonseka; Nick Maskell
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

10.  Malignant pleural mesothelioma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Byungju Kang; Mi Ae Kim; Bo Young Lee; Hwan Yoon; Dong Kyu Oh; Hee Sang Hwang; Changmin Choi
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.